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Visceral leishmaniasis (VL), the most severe form of leishmaniasis, is endemic in Europe
with Mediterranean countries reporting endemic status alongside a worrying northward
spread. Serological diagnosis, including immunochromatographic test based on the recom-
binant antigen rK39 (rK39-ICT) and a direct agglutination test (DAT) based on the whole
parasite antigen, have been validated in regions with high VL burden, such as eastern Africa
and the Indian subcontinent. To date, no studies using a large set of patients have per-
formed an assessment of both methods within Europe.
Methodology/Principal findings
We selected a range of clinical serum samples from patients with confirmed VL (including
HIV co-infection), Chagas disease, malaria, other parasitic infections and negative samples
(n = 743; years 2009–2015) to test the performance of rK39-ICT rapid test (Kalazar Detect
Rapid Test; InBios International, Inc., USA) and DAT (ITM-DAT/VLG; Institute of Tropical
Medicine Antwerp, Belgium). An in-house immunofluorescence antibody test (IFAT), was
included for comparison. Estimated sensitivities for rK39-ICT and DAT in HIV-negative VL
patients were 83.1% [75.1–91.2] and 84.2% [76.3–92.1], respectively. Sensitivity was
reduced to 67.3% [52.7–82.0] for rK39 and increased to 91.3% [82.1–100.0] for DAT in HIV/
VL co-infected patients. The in-house IFAT was more sensitive in HIV-negative VL patients,
84.2% [76.3–92.1] than in HIV/VL patients, 79.4% [73.3–96.2]. DAT gave 32 false positives
in sera from HIV-negative VL suspects, compared to 0 and 2 for rK39 and IFAT, respectively,
but correctly detected more HIV/VL patients (42/46) than rK39 (31/46) and IFAT (39/46).
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Conclusions/Significance
Though rK39-ICT and DAT exhibited acceptable sensitivity and specificity a combination
with other tests is required for highly sensitive diagnosis of VL cases in Spain. Important var-
iation in the performance of the tests were seen in patients co-infected with HIV or with other
parasitic infections. This study can help inform the choice of serological test to be used
when screening or diagnosing VL in a European Mediterranean setting.
Author summary
Visceral leishmaniasis is the most severe form of leishmaniasis, a disease transmitted
through the bite of an infected sandfly. Although the biggest burden of leishmaniasis is in
eastern Africa and the Indian subcontinent, the disease is also endemic in parts of Europe.
Previous studies have looked at performance of diagnostic methods, but not in great detail
on samples derived from a European setting. Using a large set of samples from a national
reference laboratory in Madrid, Spain, we assessed a leishmaniasis rapid test and a direct
agglutination test for serological diagnosis of visceral leishmaniasis in Europe. Both tests
were effective at diagnosing VL, but important differences were seen when testing patients
co-infected with HIV or with other parasitic infections. This study can help inform which
diagnostic tests are suitable for use in a European Mediterranean setting.
Introduction
Visceral leishmaniasis (VL) is a life-threatening disease caused by protozoan parasites of the
Leishmania donovani complex. It is widely endemic in South America, eastern Africa and Asia
as well as in the Mediterranean basin [1]. More than 500 million people are at risk of acquiring
leishmaniasis worldwide, with approximately 90% of the cases arising in rural areas of Bangla-
desh, Brazil, Ethiopia, India, Somalia, South Sudan and Sudan [2]. In Europe, nine countries
report cases of VL annually accounting for less than 2% of the global burden [3], where cases
are mostly confined to the Mediterranean countries, but a spread towards northern Europe is
being reported as a result of a range of factors, including vector and parasite migration, and
changes to the environment and climate [4]. In Spain, a VL outbreak of unprecedented magni-
tude occurred in the southwest of the capital Madrid between 2009–2013 [5,6], and the coun-
try was recently listed among the top 14 VL high-burden country [2].
Facing a possible (re-)emergence of leishmaniasis in Europe, it is important for national
public health institutions to have established guidelines for clinical diagnosis of VL to support
primary health care and epidemiological surveillance [3,7]. Parasitological confirmation
through culturing and/or microscopy remains the gold standard for diagnosis, and gives the
clearest indication of parasitic infection. The sensitivity of parasitological confirmation, how-
ever, depends on the sample used, where spleen and bone marrow aspirates yield the best
results but these are obtained through invasive sampling procedures, with inherent complica-
tions, besides presenting variable sensitivity [8]. In addition, the absence of parasites in tissue
sample does not necessarily indicate absence of infection. Nucleic acid amplification tools
have shown to be more sensitive than microscopy or culture for VL diagnosis, even when
using peripheral blood samples [9]. This technology is already available in many hospitals and
reference centers in VL-endemic countries in Europe; unfortunately there is a consistent lack
of standardization and a very high number of different protocols [9].
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Serological tools provide a good diagnostic accuracy as long as they are used in combination
with a standardized clinical case definition for VL [1]. Serological tests vary in the target anti-
gen (whole parasite or recombinant protein), ease-of-use (rapid dipstick or necessity for some
laboratory infrastructure), sensitivity, specificity, and cost. Underlying HIV infections, or
other forms of immunosuppression, however, can affect their sensitivity [10].
The rK39 immunochromatographic test (rK39-ICT) and the direct agglutination test
(DAT) have been widely validated in the VL endemic regions of eastern Africa and the Indian
subcontinent, with rK39-ICT demonstrating varying sensitivity and specificity depending on
the geographical setting [11–13].To our knowledge, no studies using a large set of patients
have performed an assessment of both methods on human samples within Europe. To estab-
lish evidence on serological VL diagnostic performance in this region, we assessed the sensitiv-




The serum samples used in this study are anonymized and are part of a registered collection,
as described below. No ethical approval was required.
Study site
The study was conducted at the WHO Collaborating Centre for Leishmaniasis, National Cen-
tre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain (WHOCCL-ISCIII), which
is also the national reference laboratory for leishmaniasis.
Characteristics of sera and study design
We used historical serum samples stored at -70˚C at the WHOCCL-ISCIII. These samples are
part of a collection registered at the National Biobank Register-Section Collections, Spain, with
collection Reference ID: C.0000898. The serum samples in the collection are anonymized.
Samples from suspected VL cases are derived from patients with clinical suspicion of VL as
defined in the protocol of the Spanish national network for epidemiological surveillance [14],
and were referred from different hospitals to the WHOCCL-ISCIII for diagnosis from 2009–
2015. Briefly, a suspected VL case in Spain is defined as a patient who presents with irregular
prolonged fever plus splenomegaly and/or weight loss, which may be accompanied by hepato-
megaly, lymphadenopathy, leukopenia, anemia and thrombocytopenia. Each suspected cases
had multiple samples (whole blood, serum, bone marrow) taken to facilitate diagnosis. While
in this study only serum samples were tested, we used all laboratory and clinical results avail-
able from each patient to classify them as “case” or “non-case”, and therefore define the refer-
ence diagnostic result (see parasitological confirmation below). Samples from VL suspects were
further divided according to the HIV status of the patients. In addition, we chose samples
from patients who were diagnosed with malaria, Chagas disease or other parasitic infections,
as well as serum from healthy individuals (blood donors) from Spain, Belgium and Germany.
All samples were anonymized and diagnostic test operators were blinded to the nature of the
serum sample.
Serological diagnostic tests
The rK39-ICT (Kalazar Detect Rapid Test, Inbios International Inc., WA, USA), and the DAT
with freeze-dried antigen (ITM-DAT/VL; Institute of Tropical Medicine, Antwerp, Belgium)
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were performed according to manufacturer’s instruction; with 20 and 1 μl serum respectively.
DAT was performed by using the screening method, samples with a titer 1:3200 were con-
sidered positive [15]. An in house IFAT was performed by following a standard method [16]:
the antigen was prepared from promastigotes of the L. infantum international reference strain
MHOM/FR/78/LEM-75. Antibody binding was detected using fluorescein isothiocyanate-
conjugated sheep anti-human immunoglobulin G (heavy and light chains). One μl serum was
used. The threshold titer for positivity was1/80. Test results were interpreted and recorded
on a standardized form by at least two observers at the minimum reading times, where each
observer was blinded to the other’s reading. Any test returning an invalid result or lack of
agreement between observers was repeated.
Parasitological confirmation
As part of routine diagnosis VL suspect patients are tested at the WHOCCL-ISCIII by nested
PCR of blood and bone marrow samples, bone marrow Giemsa microscopy and blood and
bone marrow NNN culture, following procedures described elsewhere [17,18]. A serum sam-
ple from a VL suspect was defined as pertaining to a case when there was parasitological con-
firmation of Leishmania in blood and/or bone marrow aspirate in samples taken within 21
days before or after the serum sample was taken.
Statistical analysis
The statistical software R was used with the ‘epiR’ package to determine sensitivity, specificity,
positive and negative predictive values [19,20]. Exact binomial confidence limits were calcu-
lated for test sensitivity, specificity, and positive and negative predictive values.
STARD checklist and workflow are provided as supplementary materials, S1 Table and S1
Fig respectively.
Results
A total of 743 samples from 2009–2015 were tested, of which 405 were suspected VL cases, and
338 samples as control group. Most samples were taken from March 2013 to January 2015 (Fig
1A) in hospitals from different regions in Spain, mostly from Madrid and the Mediterranean
coast (Fig 1C).
Seventy percent of suspected cases were male, with an average age of 41 years (Fig 1B). Sev-
enty-six patients were HIV positive, while 12 patients had immunosuppression related to
organ transplantation (n = 11) and Crohn’s disease (n = 1). The composition of serum samples
and the diagnostic test results is detailed in Table 1.
The sensitivity, specificity, positive and negative predictive values of each test are given in
Table 2.
A sub group analysis according to the HIV status of the VL suspect patients is shown in
Table 3.
rK39-ICT
The estimated sensitivity of rK39 was 78.0% [70.8–85.2] for all 405 suspected VL patients. Of
the 95 HIV-negative VL cases, 79 were correctly diagnosed by rK39 giving a sensitivity of
83.1% [75.1–91.2]. The sensitivity dropped to 67.3 [52.7–82.0] in individuals with underlying
HIV infection. Of the 602 negative samples (338 control subjects and 264 non-confirmed VL
suspects), rK39 gave 1 false positive in a malaria patient.
Validating serological tests for Mediterranean visceral leishmaniasis
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Fig 1. Timeline and demographics of suspected visceral leishmaniasis (VL) cases tested at the WHOCCL-ISCIII, Spain, 2009–2015. Panel A shows the number of
VL cases and non-cases tested by month. Panel B shows the age and sex distribution of suspected VL cases and non-cases. Panel C maps the location of health centres in
Spain where VL cases sought diagnosis (circles) and the number of VL cases per health centre (size of circle). Map tiles by Stamen Design, under CC BY 3.0. Data by
OpenStreetMap, under ODbL.
https://doi.org/10.1371/journal.pntd.0006277.g001
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DAT
The estimated sensitivity of DAT was 86.5% [80.5–92.5] for all 405 suspected VL patients. The
sensitivity of DAT in HIV-negative VL suspects was 84.2% [76.3–92.1], rising to 91.3% [82.1–
100.0] in individuals with underlying HIV infection. Of the 602 negative samples (338 control
subjects and 264 non-confirmed VL suspects), DAT gave false positive results for 41 serum sam-
ples, including 2 individuals with malaria and two individuals with other parasitic infections.
IFAT
The estimated sensitivity of IFAT was 79.4% [72.4–86.4] for all 405 suspected VL patients. The
sensitivity of IFAT in HIV-negative VL suspects was 84.2% [76.3–92.1] dropping to 79.4%
[73.3–96.2] in VL suspects with HIV. Of the 602 negative samples (338 control subjects and
264 non-confirmed VL suspects), IFAT gave false positives for 2 non-confirmed VL suspects
and 15 patients with Chagas disease.
Discussion
In this study, we assessed the sensitivity and specificity of rK39-ICT, DAT and IFAT on a var-
ied set of historical serum samples collected in Spain from 2009–2015. The diagnostic
Table 1. Type and number of samples used in this study and diagnostic outcome from each test assessed.
rK39-ICT DAT IFAT Parasitological
confirmation
N pos neg pos neg pos neg pos neg
Suspected VL 405 110 295 246 159 114 291 0 264
Cases 141 110 31 122 19 112 29 141 0
Non-cases 264 0 264 37 227 2 262 0 264
Control groups 338 1 337 4 334 15 323 NA NA
Chagas disease 51 0 51 0 51 15 36 NA NA
Malaria 55 1 54 2 53 0 55 NA NA
Other parasitoses 57 0 57 2 55 0 57 NA NA
Spanish blood donors 142 0 142 0 142 0 142 NA NA
German blood donors 13 0 13 0 13 0 13 NA NA
Belgian blood donors 20 0 20 0 20 0 20 NA NA
Total 743 111 632 163 580 129 614
Positive parasitological confirmation by either nested PCR in blood or bone marrow, Giemsa microscopy in bone marrow aspirate or NNN-culture of blood and/or
bone marrow samples.; NA = not applicable, as parasitological confirmation for Leishmania infection was not performed in this group; pos = positive results;
neg = negative result.
https://doi.org/10.1371/journal.pntd.0006277.t001
Table 2. Performance of rK39, DAT and IFAT on suspected visceral leishmaniasis samples in Spain, 2009–2015. Sensitivity (Sn), specificity (Sp), positive predictive
value (PPV), negative predictive value (NPV) with 95% confidence intervals [].
rK39-ICT DAT IFAT
Sn 78.0% [70.8–85.2] 86.5% [80.5–92.5] 79.4% [72.4–86.4]
Sp 100.0% [99.8–100.0] 85.9% [81.6–90.3] 99.2% [98.0–100.0]
PPV 100.0% [99.5–100.0] 76.7% [69.8–83.6] 98.2% [95.4–100.0]
NPV 89.5% [85.8–93.1] 92.3% [88.7–95.8] 90.0% [86.4–93.6]
Sn: Sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value.
https://doi.org/10.1371/journal.pntd.0006277.t002
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performance of rK39-ICT and DAT has been largely evaluated in highly endemic country set-
tings [12], with variable results in different geographic locations for rK39-ICT [21], and the
performance in a European setting remains largely unknown. A multicenter study compared
different diagnostic tests using samples from 26 HIV-negative and 11 HIV-positive VL
patients from southern France [22]. This study evaluated a different rK39-ICT (IT-LEISH Bio
Rad Laboratories, France) and DAT (the same as in our study), among other serological tests,
and obtained a sensitivity of 88.5% for both in HIV-negative VL patients and 54.5% for DAT
and 81.8% for rK39-ICT in HIV/VL patients. In a study from Italy with a sample size of 94
patients with suspected VL (21 patients were confirmed VL cases), the reported sensitivity of
rK39-ICT was 52.4%, using a different manufacturer than in our study [23]. These results dif-
fered from our study, which are more in agreement with other large scale evaluations of
rK39-ICT and DAT that show higher sensitivity for DAT in a setting with high HIV-co-infec-
tion rate [24].
The evaluation of diagnostic tools for visceral leishmaniasis in Europe is important as the
burden of VL remains an issue for European public health officials [3]. We began addressing
this issue using a large assembly of samples. Our results show lower sensitivity estimates when
compared to published results on serological assay evaluation in South East Asia, the Americas
and eastern Africa regions. In a meta-analysis of diagnostic performance, the combined sensi-
tivity estimates of DAT and the rK39-ICT were 94.8% and 93.9%, respectively [25], while in
our study, the estimated DAT and rK39-ICT sensitivity was at 86.5% and 78.0%, respectively.
In a WHO led evaluation of rK39-ICT, the sensitivity estimates varied greatly from region to
region: 67.6% in eastern Africa, 84.7% in Brazil and 99.6% on the Indian subcontinent [21].
The different performance of serological tests between European samples and those tested
elsewhere is most likely due to the epidemiological landscape. Patients residing outside of
Europe will have different anti-VL immunoglobulin titers, different age patterns of infection,
immune and/or nutritional background and/or are exposed to higher parasite diversity [21]. A
study analyzing L. donovani strains from African and Asian origin revealed extensive genetic
diversity in coding sequences of rK39 homologues, which may provide an explanation for the
different performance of rK39-ICT across regions [26]. In the Mediterranean region VL is
caused by different genetic variants of L. infantum [27,28], whether this has an effect on the
performance of rK39-ICT would be an interesting subject of study.
Our study sample reflects a population living in a southern European member state where
samples are routinely submitted for laboratory diagnosis after clinical suspicion of VL. Of the
Table 3. Sub group analysis on HIV status. Performance of rK39, DAT and IFAT on suspected visceral leishmaniasis samples in Spain, 2010–2014. Sensitivity (Sn), spec-
ificity (Sp), positive predictive value (PPV), negative predictive value (NPV) with 95% confidence intervals [].
HIV POSITIVE (n = 76) rK39-ICT DAT IFAT
Sn 67.3% [52.7–82.0] 91.3% [82.1–100] 79.4% [73.3–96.2]
Sp 100.0% [98.3–100] 83.3% [68.3–98.3] 99.2% [98.3–100]
PPV 100.0% [98.4–100] 89.3% [79.5–99.2] 98.2% [98.7–100]




Sn 83.1% [75.1–91.2] 84.2% [76.3–92.1] 84.2% [76.3–92.1]
Sp 100.0% [99.8–100] 86.3% [81.7–90.9] 86.3% [81.7–90.9]
PPV 100.0% [99.4–100] 71.4% [62.6–80.2] 71.4% [62.6–80.2]
NPV 93.6% [90.4–96.8] 93.1% [89.5–96.7] 93.1% [89.5–96.7]
Sn: Sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value.
https://doi.org/10.1371/journal.pntd.0006277.t003
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405 samples submitted between 2009 and 2015 and analyzed in this study, 34% were classified
as cases. To expand our sample population and assess the performance of serological tests with
respect to cross-reactivity, we further selected confirmed VL negative serum samples with
varying immunological exposures, including Chagas disease, caused by another member of the
Trypansomatidae family, as well as German and Belgian blood donors who are less likely to
have had previous parasite exposure.
Although sensitivity and specificity varied between diagnostic tests, we found that the in
house IFAT, rK39-ICT (Kalazar Detect from InBios International, Inc.) and DAT (ITM-DAT/
VL, Institute of Tropical Medicine, Antwerp) are valid for VL diagnosis in Europe. The choice
of test, however, is according to the epidemiological context and intended application. In the
context of VL in Europe we find three main applications for serological tests: seroprevalence
studies, clinical diagnosis and outbreak response tools.
Seroprevalence studies involve large-scale screening of samples to determine the burden of
disease in a given population. Previous prevalence studies in Europe on blood donors have
used different immunological and/or molecular tests [29–31]. Based on our results, we find
DAT performed best for seroprevalence studies, with the ability to batch process samples, the
acceptable costs, and the specificity and sensitivity values at 86% and 85%, respectively.
For clinical diagnosis, the choice of test depends partly on the immunological status of the
patient. In our study, co-infection with HIV reduced the sensitivity of rK39-ICT, making it
less applicable for a point-of-care test in HIV individuals in Spain. During the community out-
break of VL in Madrid, 16 out of 160 reported VL cases (10%) had HIV [5], and could there-
fore have been missed if rK39 was used as sole diagnostic. In a series of 73 VL patients (66%
immunocompetent) from that outbreak, another rK39-ICT (SD BIOLINE Leishmania Ab,
Standard Diagnostics, Inc., South Korea) showed 67% sensitivity and 100% positive predictive
value [32]. To our surprise, in our study the DAT showed higher sensitivity in HIV-positive
patients. Although a higher sensitivity in this group is somehow unexpected, it is important to
highlight that DAT has returned acceptable sensitivity in the diagnosis of VL in HIV-positive
patients, being superior to other serological tests [10,24,33–35]. It is difficult for us to find an
explanation to this, and it could be suggested that the observed discrepancy may be due to the
difference in the number of patients in each group; being only relevant for rK39-ICT (the only
test using a single antigen), for which the different performance according to the HIV status is
especially marked. A study specifically designed to assess differences in the diagnostic perfor-
mance of the tests according to the HIV status would be necessary to address this properly. We
did not conduct a separate analysis in patients with other immunosuppressive conditions as
previous studies have shown that the diagnostic sensitivity of serological tests is not decreased
in patients receiving solid organ transplants, which were 11 out of 12 of our suspected VL
cases with immunosuppressive conditions other than HIV [36–38].
During outbreak settings such as those seen in Madrid in 2009–2013, point-of-care tests
like rK39-RDT have the benefit of portability, simplicity and the speed of result, allowing
quick identification and control of infection clusters. In our study we used all laboratory (PCR,
culture, serology) and clinical results available from each patient to classify them as “case” or
“non-case”. The reported sensitivities of the serological tests included in this study justify the
algorithm proposed for VL diagnosis in the WHO European region, where rK39-ICT is first
used in VL suspected cases and can be complemented with other serological or parasitological
tests to ensure accurate diagnosis [3]. The rK39-ICT is a simple, fast, commercially available
test that uses a less invasive sample. The application of this test for VL diagnosis and subse-
quent treatment of confirmed cases with liposomal amphotericin B, the reference treatment
for VL in the WHO European Region [3], has shown to be cost-effective for Mediterranean
VL management in Morocco [39].
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In terms of cross reactivity, we found that all true negative serum samples from blood
donors from Belgium, Germany and Spain were diagnosed as negative for VL by DAT and
rK39-ICT. Some false positive results were obtained with Chagas disease patients and those
with other parasitic infections, this was particularly pronounced for the IFAT, a widely used
serological test for VL diagnosis in Europe. This can be explained by serological cross reactivity
between trypanosomatids [40]. In order to account for this, other infections such as Chagas
disease, malaria or other parasites should be routinely discarded to increase diagnostic accu-
racy. This is particularly important in diagnosing a patient who has resided in or visited a
country endemic for other parasitic disease, such as is common in the Spanish migrant popula-
tions [41].
To the best of our knowledge this is the first large-scale evaluation of rK39-ICT and DAT
for VL diagnosis in Europe. These results can inform public health practitioners in the region
on the strengths and limitations of serological diagnosis. In addition to serology, however,
PCR diagnosis should always be considered for confirmation of infection, and for the added
benefit that molecular characterization brings.
Finding appropriate diagnostic solutions to VL is not only important to contain the burden
of this Neglected Tropical Disease, but it will also help in the implementation of the United
Nations Sustainable Development Goal of Universal Health Coverage [42].
Supporting information
S1 Table. STARD checklist. Detailed list of items related to reporting of diagnostic accuracy
studies.
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